Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02259322 · ClinicalTrials.gov registry record · NA
Loss of Control Eating Following Weight Loss Surgery
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT02259322: Completed NA study, sponsored by Yale University.
NCT02259322 is a NA study that has completed, run by Yale University. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02259322, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will test the effectiveness of two distinct behavioral treatments for loss of control eating following bariatric surgery: 1. Behavioral Weight Loss Treatment 2. Cognitive Behavioral Therapy These treatments will be compared to Standard-of-Care.
Primary Outcome
Loss of Control eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency is defined categorically (presence or absence of loss of control eating).
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy
- BEHAVIORAL Standard-of-Care
- BEHAVIORAL Behavioral Weight Loss Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-09 |
| Est. Completion | 2018-07 |
| Phase | NA |
What the finished NCT02259322 record still lists
NCT02259322 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Cognitive Behavioral Therapy is the first listed.
NCT02259322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02259322 about?
NCT02259322 is a clinical study titled "Loss of Control Eating Following Weight Loss Surgery". This study will test the effectiveness of two distinct behavioral treatments for loss of control eating following bariatric surgery: 1. Behavioral Weight Loss Treatment 2. Cognitive Behavioral Therapy These treatments will be compared to Standard-of-Care.
What is the current status of trial NCT02259322?
This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2014-09. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02259322?
The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL), Standard-of-Care (BEHAVIORAL), Behavioral Weight Loss Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT02259322?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02259322's enrollment target sits among peer trials
140 713th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia